Blockchain data analysis company Bitrace issued a statement stating that some buyers of virtual goods or services use the purchased virtual goods or services for risky encryption activities, and further use illegal gains as purchase fees for secondary payments, resulting in sellers and The cryptographic addresses of other normal buyers were tainted, causing widespread financial risks. The three types of anonymous market capital risks listed in the article include purchasing good numbers for opening casinos, customizing specific tail number addresses for fishing, and purchasing Telegram robot services for illegal currency exchange.

Regarding the third type of risk, Bitrace said that taking the more common currency exchange robots as an example, these robots allow anyone to transfer money to their business address and automatically exchange it. The main trading pair is trx/usdt to satisfy ordinary on-chain users. small currency exchange needs. Research has found that there are a large number of gambler addresses, money laundering addresses, stolen currency addresses and even fraudulent addresses among these currency exchangers; if the currency exchanger's funds are at risk, it will also cause pollution to the service provider's address.

Bitrace recommends that users try to conduct transactions in a strong real-name environment. If you purchase virtual goods or services and exchange tokens over-the-counter in anonymous online markets, it is possible that: 1. Your address will be permanently associated with a high-risk capital risk address. Your resume on the chain will be damaged as a result; 2. If you collect the funds involved, it may lead to investigation by law enforcement agencies, resulting in the funds on the chain being frozen; 3. The centralized trading platform account associated with your address may be marked as high by the platform. risks and face higher-level risk control measures.

In response to the pressure of rising prices, this company will import 1.3 billion Chinese medicinal materials from overseas

In June of this year, domestic Chinese medicinal materials were uncharacteristically, and the phenomenon of "not being weak in the off-season" appeared, and the prices of many varieties rose sharply, which directly promoted the increase in production costs of Chinese medicine companies. In response to the pressure of rising prices, some companies began to choose to increase their efforts to import Chinese herbal medicines from overseas.

The first financial reporter learned from Guangzhou Pharmaceutical Group that on July 18, Caizhilin Pharmaceutical of Guangzhou Pharmaceutical Group established a strategic partnership with Chinese medicinal material suppliers from Russia and Indonesia. Caizhilin Pharmaceutical will purchase nearly 20,000 tons of Chinese medicinal materials such as licorice, astragalus, windproof, and schisandra from Russia Newland Co., Ltd. for five consecutive years, and nearly 10,000 tons of traditional Chinese medicinal materials such as frangipani from Indonesia Xintiandi Local Products Trading Co., Ltd.

These two countries have their own advantages in traditional Chinese medicine resources. Russia is located in a high-latitude alpine region, rich in biodiversity, and has authentic medicinal materials such as Schisandra chinensis and Astragalus membranaceus. Indonesia is one of the main producing areas of frangipani, with a large output and high quality of frangipani.

According to reports, the two sides of the cooperation will also actively carry out the cultivation, planting, breeding, production and processing of key medicinal materials and rare animal medicinal materials, establish a joint research and development platform for Chinese medicinal materials, and jointly carry out standardization of Chinese medicinal materials and research on key core technologies of provenance, so as to improve the technical level and innovation capabilities of the Chinese medicinal materials industry.

Regarding this import, Wu Changhai, deputy general manager of Guangzhou Pharmaceutical Group, said that the company is actively opening up domestic and international traditional Chinese medicine integration channels, introducing high-quality and cheap overseas Chinese medicinal material resources, helping to alleviate the pressure of rising prices of domestic Chinese medicinal materials, and promoting the cost reduction and efficiency enhancement of the Chinese medicine industry.

There are many varieties of Chinese medicinal materials in my country, but large-scale planting has not yet been formed, which to a certain extent has also led to fluctuations in the price of Chinese medicinal materials.

Imported medicinal materials are an important part of my country's medicinal materials resources, and most of the exporting countries of medicinal materials are countries along the "Belt and Road". In January 2020, my country's new version of the "Measures for the Administration of Imported Medicinal Materials" was officially implemented to encourage the import of medicinal materials, implement the "Belt and Road" initiative, and embody the spirit of "connectivity".

At present, my country's traditional Chinese medicine exports are still higher than imports. According to data from the China Chamber of Commerce for Import and Export of Medicines and Health Products, in 2022, my country's foreign trade in traditional Chinese medicine will total US$8.57 billion, a year-on-year increase of 10.7%. Among them, the export value was US$5.69 billion, a year-on-year increase of 13.8%; the import value was US$2.88 billion, a year-on-year increase of 5.1%. The top ten varieties of imported Chinese medicinal materials (in terms of import value) are American ginseng, velvet antler, ginseng, turmeric, saffron, licorice, clove, dried blood, frankincense, and myrrh. The import value of the top ten varieties accounts for 36% of my country's total import of medicinal materials. In 2022, the top ten source countries (in terms of import value) of my country's imported medicinal materials are Indonesia, Myanmar, Canada, New Zealand, South Korea, India, Thailand, Vietnam, Russia, and the United States, accounting for 85% of my country's total imports of Chinese medicinal materials and 87% of the total import value.

Guangzhou Pharmaceutical Group said that the company will continue to conduct in-depth research on the production and supply of foreign Chinese medicinal materials in the future, and continue to open up domestic and foreign markets for Chinese medicinal materials.